Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122444) titled 'Phase II Clinical Study of Sacituzumab Tirumotecan in Combination with Toripalimab as Neoadjuvant Therapy for Resectable Stage II-IIIA NSCLC' on April 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute)
Condition:
Resectable non-small cell lung cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-15
Target Sample Size: Test group:28;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...